HeartSciences (HSCS) FQ1 2027 Financial Results Summary
QuoteReporter
HeartSciences (HSCS) Q1 2027: Revenue Miss, Losses Widen — Cautiously Disappointing
HeartSciences Inc. (Nasdaq: HSCS) reported its fiscal first quarter 2027 financial results, revealing a disappointing performance compared to the previous year. The company reported no meaningful revenue for the quarter, resulting in a net loss of $3.2 million, which is an increase of $1.1 million or +52% from the net loss of $2.1 million in the same quarter last year.
Key Financial Metrics:
- Revenue: No meaningful revenue reported for FQ1 2027.
- Net Loss: $3.2 million (FQ1 2026: $2.1 million), an increase of $1.1 million or +52% YoY.
- Loss from Operations: $2.9 million (FQ1 2026: $1.9 million), an increase of $1.0 million or +53% YoY.
- Legal and Professional Costs: Increased by approximately $0.5 million due to the Proposed Transaction with Fortitude.
- Inventory Reserve: $0.3 million recorded against the remaining carrying value of related inventory.
Analyst View
This quarter can be viewed as disappointing for shareholders, primarily due to the lack of revenue generation and the widening losses. The increase in operational losses, driven by higher legal and professional costs associated with the proposed business combination with Fortitude, raises concerns about the company's financial health and operational efficiency. The absence of revenue highlights the challenges HeartSciences faces in commercializing its MyoVista Insights platform, despite positive feedback from clinicians.
Business Developments
HeartSciences is focusing its efforts on the MyoVista Insights platform, which has seen some progress:
- Commercial Agreements: The company signed its first U.S. commercial agreements following the full launch of MyoVista Insights.
- AI-ECG Algorithm Marketplace: The platform now features the first third-party FDA-cleared AI-ECG algorithm.
- European Reference Center: MyoVista Insights was selected as the ECG management and AI-ECG delivery platform for a major European reference center, with expectations for expansion into a larger multicenter project.
Despite these advancements, the company has recorded a reserve against the MyoVista wavECG device, indicating a shift in focus away from this product due to the complexities of commercialization and the emergence of cloud-based AI-ECG algorithms.
Capital and Shareholder Updates
As of July 31, 2026, HeartSciences reported a shareholders’ deficit of $2.0 million. However, since the end of the quarter, the company has raised approximately $1.0 million from a sale of common stock to Fortitude and net proceeds of approximately $1.2 million from sales made under its at-the-market facility. These capital raises are crucial for maintaining liquidity as the company navigates its operational challenges.
Forward Catalyst
Investors should closely monitor the progress of the proposed business combination with Fortitude, expected to close in Q4 calendar 2026, as it may provide new opportunities for growth and exposure to the Zcash ecosystem. Additionally, the upcoming developments in the commercialization of MyoVista Insights and the FDA review of the MyoVista wavECG device will be critical indicators of the company's ability to generate revenue in the near future.
In summary, while HeartSciences is making strides in its technology and partnerships, the financial results for Q1 2027 reflect significant challenges that need to be addressed for the company to regain investor confidence and drive shareholder value.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
*Amounts in thousands*
| FQ1 2027 | FQ1 2026 | |
|---|---|---|
| Revenue | 0 | 0 |
| Loss from Operations | (2,900) | (1,900) |
| Net Loss | (3,200) | (2,100) |
CONDENSED CONSOLIDATED BALANCE SHEETS
*Amounts in thousands*
| July 31, 2026 | April 30, 2026 | |
|---|---|---|
| Cash and Cash Equivalents | XX,XXX | XX,XXX |
| Total Assets | XX,XXX | XX,XXX |
| Total Liabilities | XX,XXX | XX,XXX |
| Shareholders' Equity | (2,000) | XX,XXX |
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
